Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-432 adjuvant selpercatinib vs placebo in stage IB–IIIA RET fusion-positive NSCLC
2020-005191-35Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Selpercatinib with Placebo (2 arms). Primary endpoints: Event-free survival in primary analysis population and Event-free survival in overall population. Started May 2021; status: active.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-005191-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005191-35.